FDA warning letters to 30 compounders, the Hims/Novo Nordisk settlement, and ongoing pharmaceutical litigation signal tightening oversight of the compounded GLP-1 market
Primary Claim: 46% More Weight Loss According to publicly available disclosures on the company's website, Ivm Health states that "Ivim patients following the Ivim Protocol lost an average of 46% more weight over 68 weeks when compared to another published clinical GLP-1 trial that included a daily 500-calorie deficit, 150 minutes of weekly exercise, and in-person counseling every four weeks." The company explicitly states this was "not a head-to-head study," meaning Ivm patients were not directly randomized against a control group in the same trial
Scramble 2 whole eggs with cup diced tomatoes, cup chopped mushrooms, and cup diced onions in 1 teaspoon of olive oil
Semaglutide vs Tirzepatide: Side-by-Side Comparison The table below summarises the key parameters and trial data for a quick Semaglutide vs Tirzepatide reference
You feel the burn as you sweat, stretch and strengthen to energize your entire body
